Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CMPS Catalyst Timeline
Dated clinical, regulatory and corporate events for COMPASS Pathways Plc - American Depository Shares
Catalyst Timeline
Dated clinical, regulatory & corporate events for COMPASS Pathways Plc - American Depository Shares
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How CMPS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-05 | COMP360 psilocybin | Phase 3 data presentation | Phase 3 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| COMP360 Small MoleculesNCT05711940 | Treatment Resistant Depression | Phase 3 | ACTIVE NOT_RECRUITING | 1,082 | Dec 1, 2026 | ||||||
| COMP360 psilocybin Small MoleculesNCT07570654 | PTSD - Post Traumatic Stress Disorder | Phase 2/3 | RECRUITING | 300 | Sep 1, 2029 | ||||||
| COMP360 Small MoleculesNCT05733546 | Major Depressive Disorder | Phase 2 | ACTIVE NOT_RECRUITING | 122 | Sep 1, 2025 | ||||||
| COMP360 Small MoleculesCompletedNCT05312151 | Post Traumatic Stress Disorder | Phase 2 | COMPLETED | 22 | Feb 12, 2024 | ||||||
| COMP360 Small MoleculesCompletedNCT05481736 | Anorexia Nervosa | Phase 2 | COMPLETED | 48 | Nov 18, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every CMPS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| COMP360 Breakthrough | treatment-resistant depression | Phase 3 | 2026-09-09 | 52-week resultsRead More | Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 YearRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Karydas DaphneDirector | Grant/Award | 21,110 21,110 held | $0.00 | 05/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CMPS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 2.5 % | 151.29 M | 12.16 M |
Ownership Trends
CMPS Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How CMPS ranks across every disease it competes in
CMPS News
Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th
Compass Pathways will attend the Jefferies Global Healthcare Conference on November 18 and 19, 2026. Management will engage in a fireside chat and a panel discussion, focusing on their innovative mental health treatments. The company is advancing its investigational psilocybin treatment, COMP360, for treatment-resistant depression and PTSD.
Read more →Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
Compass Pathways has submitted a New Drug Application (NDA) to the FDA for COMP360 psilocybin, targeting treatment-resistant depression (TRD). The submission is backed by data from two Phase 3 trials and a Phase 2b study involving over 1,000 participants. The company aims for a commercial launch in H1 2027, pending FDA approval.
Read more →Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Pathways announced the granting of equity awards to nine new employees under its 2026 Inducement Plan. The awards include options for 59,275 shares and restricted share units, with an exercise price of $8.41. This move is part of the company's strategy to attract talent while advancing its mental health treatment initiatives.
Read more →Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
Compass Pathways will attend the Stifel 2026 Healthcare Conference on November 11, 2026. Management will participate in a fireside chat at 8:40am ET. The company is focused on developing COMP360, a synthetic psilocybin treatment for treatment-resistant depression and PTSD, which has received FDA Breakthrough Therapy designation.
Read more →Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
Compass Pathways reported its Q3 2026 financial results, highlighting the imminent NDA submission for COMP360, expected within two weeks. The company anticipates a launch in H1 2027, pending FDA approval. Positive Phase 3 trial data suggests COMP360 could redefine treatment for treatment-resistant depression (TRD), addressing a significant market need.
Read more →New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers
Compass Pathways and DBSA released a survey revealing the significant burden of treatment-resistant depression (TRD) on patients and caregivers. The survey indicates that 95% of patients feel they are merely surviving, with many reporting emotional exhaustion from ineffective treatments. Caregivers also face substantial emotional and financial strains, highlighting the urgent need for improved treatment options.
Read more →Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress
Compass Pathways will participate in the 2026 Neuroscience Education Institute Fall Congress, focusing on treatment-resistant depression (TRD). The company will present its educational campaign, 'Change the Tune in TRD,' and encore presentations from its COMP360 psilocybin clinical program. This event aims to enhance understanding among U.S. healthcare professionals.
Read more →Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026
Compass Pathways plc will announce its third quarter 2026 financial results on November 3, 2026. The company will also provide updates on recent developments during a conference call at 8:00 am ET. Compass is focused on developing COMP360 psilocybin for treatment-resistant depression and PTSD, with significant designations from regulatory bodies.
Read more →Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day
Compass Pathways has announced the first-ever Treatment-Resistant Depression (TRD) Awareness Day in the U.S., aimed at raising awareness about the condition and its impact on patients and caregivers. The initiative is supported by major mental health organizations and seeks to foster understanding and support for those affected by TRD. A report detailing the burden of TRD will be released in the future.
Read more →Compass Pathways Celebrates Opening of New U.S. Office in Jersey City, New Jersey
Compass Pathways has inaugurated its new U.S. office in Jersey City, New Jersey, which will serve as a hub for its employees in the tri-state area. This 6,327-square-foot facility aims to support the company's efforts in advancing its investigational treatment, COMP360, for treatment-resistant depression. The CEO highlighted the importance of this milestone in the company's growth and commitment to improving mental health care.
Read more →Compass Pathways Appoints Kelley Boucher as Chief People Officer
Compass Pathways has appointed Kelley Boucher as Chief People Officer, effective immediately. This strategic move aims to strengthen the executive team as the company focuses on scaling its operations. The appointment aligns with Compass's mission to introduce innovative psychedelic treatments in psychiatry.
Read more →Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
Compass Pathways plc will participate in the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026. The company will host a fireside chat at 1:00 pm ET, which will be available via a live audio webcast. Compass is focused on developing innovative treatments for mental health, including its investigational psilocybin treatment, COMP360.
Read more →Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
Compass Pathways has launched the 'Change the Tune in TRD' initiative aimed at enhancing healthcare provider understanding of treatment-resistant depression (TRD). This campaign will delve into the neurobiology of TRD and assist in navigating care pathways for both patients and providers. The initiative was announced during the Psych Congress 2026.
Read more →Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360
Strata Mental Health Solutions has received a grant from Compass Pathways to develop training programs for healthcare providers regarding COMP360, an investigational psilocybin treatment. This initiative aims to prepare clinical networks for the potential delivery of psychedelic treatments. The collaboration highlights Strata's expertise in the field.
Read more →Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
Fluence has been selected by Compass Pathways to develop a certificate program for healthcare providers in anticipation of the FDA's approval of COMP360, a psilocybin treatment for depression. The program will consist of three modules aimed at equipping clinicians with the necessary skills and knowledge to support patients. This collaboration emphasizes Fluence's dedication to translating research into clinical practice.
Read more →Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
Compass Pathways has announced the recipients of its U.S. grant program aimed at developing training for healthcare providers to deliver COMP360, a psilocybin treatment for treatment-resistant depression. The program awarded grants to five organizations, expanding from the initial plan of three due to high-quality applicants. This initiative is part of Compass's commitment to ensuring effective treatment delivery upon COMP360's potential approval.
Read more →Compass Pathways to Participate in Investor Conferences the Week of September 14th
Compass Pathways plc will participate in investor conferences during the week of September 14th. The company aims to engage with investors at the H.C. Wainwright Annual Global Investment Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. These events will provide a platform for discussing their innovative approaches in mental health care.
Read more →Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year
Compass Pathways has released topline results from the Phase 3 COMP005 trial of COMP360, a psilocybin formulation for treatment-resistant depression. The open-label Part C data indicates an additional benefit from another dose, extending the treatment's durability to one year. This supports the drug's differentiated profile and potential for long-term effectiveness.
Read more →Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026
Compass Pathways is set to launch its 'Change the Tune in TRD' education campaign at Psych Congress 2026, focusing on treatment-resistant depression (TRD). The company will also present new health economics and outcomes research data, alongside findings from its COMP360 psilocybin clinical trials. This initiative aims to enhance healthcare provider education on TRD.
Read more →